Alnylam Pharmaceuticals and GENESIS Pharma partner to commercialize patisiran in South East Europe
GENESIS Pharma announces a commercialization agreement with Amicus Therapeutics® for migalastat in Greece, Cyprus, Romania and Bulgaria.
Migalastat is the first oral treatment as well as the first precision medicine for Fabry disease.
[Athens, Tuesday 12 March 2019] GENESIS Pharma, a leading regional biopharma company operating in the broader region of Southeast Europe, announces that Amicus Therapeutics, a biotechnology company at the forefront of rare and orphan diseases, has granted the company exclusive rights to commercialize migalastat in Greece, Cyprus, Romania and Bulgaria. The European Commission granted full approval of migalastat in May 2016. Under the terms of the agreement, GENESIS Pharma will be responsible for the sales and marketing, medical affairs, regulatory and reimbursement support for migalastat in the above markets.